UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

Leukemia, 2007-04, Vol.21 (4), p.627-632

2007

Volltextzugriff (PDF)

THU0061 Anemia in patients with rheumatoid arthritis: A cross-sectional study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.173-173

2013

Volltextzugriff (PDF)

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations

Leukemia, 2017-04, Vol.31 (4), p.882-888

2017

Volltextzugriff (PDF)

A unified definition of clinical resistance intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

Leukemia, 2007-02, Vol.21 (2), p.277-280

2007

Volltextzugriff (PDF)

Too-low iron doses and too many dropouts in negative iron trial?

Journal of clinical oncology, 2011-06, Vol.29 (17), p.e525-e526

2011

Volltextzugriff (PDF)

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Journal of clinical oncology, 2011-02, Vol.29 (6), p.761-770

2011

Volltextzugriff (PDF)

Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients

JOURNAL OF CLINICAL ONCOLOGY, 2011-05, Vol.29 (15_suppl), p.6610-6610

2011

Volltextzugriff (PDF)

Five-year follow-up of survival and relapse in patients who received cryotherapy during high-dose chemotherapy for stem cell transplantation shows no safety concerns

European journal of cancer care, 2012-11, Vol.21 (6), p.822-828

2012

Volltextzugriff (PDF)

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

LEUKEMIA, 2008-02, Vol.22 (2), p.462-462

2008

Volltextzugriff (PDF)

Anagrelide Treatment in Myeloproliferative Disorders

Seminars in thrombosis and hemostasis, 2006-04, Vol.32 (3), p.260-266

Birgegard, Gunnar

2006

Volltextzugriff (PDF)

Does anything work for anaemia in myelofibrosis?

Best practice & research. Clinical haematology, 2014-06, Vol.27 (2), p.175-185

Birgegard, Gunnar

2014

Volltextzugriff (PDF)

A unified definition of clinical resistance intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

Leukemia, 2007-05, Vol.21 (5), p.1136-1136

2007

Volltextzugriff (PDF)

The role of iron supplementation during epoietin treatment for cancer-related anemia

Medical oncology (Northwood, London, England), 2009-03, Vol.26 (1), p.105-115

2009

Volltextzugriff (PDF)

CIRCADIAN VARIATION OF GRANULOCYTE COLONY‐STIMULATING FACTOR LEVELS IN MAN

British journal of haematology, 2000-03, Vol.108 (3), p.661-661

Birgegard, Gunnar

2000

Volltextzugriff (PDF)

Quality of life, physical function and MRI T2in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

European journal of haematology, 2011-09, Vol.87 (3), p.244

2011

Volltextzugriff (PDF)

A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia : Feasibility, clinical and biologic effects, and impact on quality of life

Cancer, 2006-06, Vol.106 (11), p.2397-2405

2006

Volltextzugriff (PDF)

Long-term management of thrombocytosis in essential thrombocythaemia

Annals of hematology, 2009-01, Vol.88 (1), p.1-10

Birgegård, Gunnar

2009

Volltextzugriff (PDF)

High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio

Medical oncology (Northwood, London, England), 2010-03, Vol.27 (1), p.105-107

2010

Volltextzugriff (PDF)

Treatment of high risk ET – data from the EXELS study

Leukemia research, 2016-05, Vol.44, p.S7-S8

2016

Volltextzugriff (PDF)

Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation

British journal of haematology, 1989-07, Vol.72 (3), p.462-466

1989

Volltextzugriff (PDF)

PSY98 - COST-EFFECTIVENESS ANALYSIS OF FERRIC MALTOL VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA IN IBD PATIENTS IN SWEDEN AND FINLAND

Value in health, 2018-10, Vol.21, p.S452-S453

2018

Volltextzugriff (PDF)

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET

Leukemia, 2015-01, Vol.29 (1), p.20

2015

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(54)
Science & Technology
(54)
Humans
(53)
Medicin Och Hälsovetenskap
(30)
Hematology
(29)
Medicine
(26)
Oncology
(22)
Medicin
(21)
Female
(18)
Male
(18)
Biological And Medical Sciences
(15)
Medical Sciences
(13)
Ferritins - Blood
(12)
Sweden
(10)
Hematologic And Hematopoietic Diseases
(9)
Erythropoietin - Therapeutic Use
(8)
Internal Medicine
(8)
Medicine & Public Health
(8)
Anemia
(7)
Anemia - Drug Therapy
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

THU0061 Anemia in patients with rheumatoid arthritis: A cross-sectional study

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations

A unified definition of clinical resistance intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

Too-low iron doses and too many dropouts in negative iron trial?

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients

Five-year follow-up of survival and relapse in patients who received cryotherapy during high-dose chemotherapy for stem cell transplantation shows no safety concerns

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

Anagrelide Treatment in Myeloproliferative Disorders

Does anything work for anaemia in myelofibrosis?

A unified definition of clinical resistance intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

The role of iron supplementation during epoietin treatment for cancer-related anemia

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

CIRCADIAN VARIATION OF GRANULOCYTE COLONY‐STIMULATING FACTOR LEVELS IN MAN

Quality of life, physical function and MRI T2in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions

A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia : Feasibility, clinical and biologic effects, and impact on quality of life

Long-term management of thrombocytosis in essential thrombocythaemia

High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio

Treatment of high risk ET – data from the EXELS study

Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation

PSY98 - COST-EFFECTIVENESS ANALYSIS OF FERRIC MALTOL VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA IN IBD PATIENTS IN SWEDEN AND FINLAND

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET

Aktive Filter

Suchergebnisse filtern